Scott joined AMRI in 2021 to lead Corporate Development, including AMRI’s mergers and acquisitions (M&A). He brought 25 years of experience to the role, as both a Corporate Development/M&A executive as well as a General Counsel and corporate lawyer, with more than 15 years in the pharmaceutical and pharmaceutical services industries.

Most recently Scott served as an advisor to private equity firms and select pharma industry clients, supporting the identification and evaluation of acquisition targets, and developing growth strategies across the pharmaceutical services industry. Previously, Scott spent 10 years at Lonza Group, including the last five years as Chief Strategy Officer, where he led Lonza’s M&A and strategic corporate transactions.  He served as U.S. General Counsel at Lonza where he managed Lonza’s legal affairs for North America covering corporate, commercial and litigation matters.  Scott previously served as associate general counsel for Enzon Pharmaceuticals. Prior to those roles, he was an associate in the private equity group at the Weil, Gotshal law firm in New York and a corporate associate at the Sidley Austin law firm in New York.

Scott earned his J.D. degree from New York University School of Law and his B.S. in Accounting from the State University of New York at Binghamton.

Scott Waldman